Locomotor response to levodopa in fluctuating Parkinson’s disease

The aim of this study was to quantify the dynamic response of locomotion to the first oral levodopa administration of the day in patients with fluctuating Parkinson’s disease (PD). Stride length, walking speed, cadence and gait variability were measured with an ambulatory gait monitor in 13 PD patients (8 males) with a clinical history of motor fluctuations. The Unified Parkinson’s Disease Rating Scale (UPDRS) gait score (part 29) was also determined by a movement disorders specialist from video recordings. Subjects arrived in the morning in an ‘off’ state (no PD medication) and walked for a maximum length of 100 m. They then took their usual morning dose of oral levodopa and repeated the walking task at 13 min intervals (on average) over a 90 min period. Changes in stride length over time were fit with a Hill (Emax) function. Latency (time until stride length increased 15% of the difference between baseline and maximum response) and the Hill coefficient (shape of the ‘off–on’ transition) were determined from the fitted curve. Latency varied from 4.7 to 53.3 min post-administration [23.31 min (SD 14.9)], and was inversely correlated with age at onset of PD (R = −0.83; P = 0.0004). The Hill coefficient (H) ranged from a smooth hyperbolic curve (0.9) to an abrupt ‘off–on’ transition (16.9), with a mean of 8.1 (SD 4.9). H correlated with disease duration (R = 0.67; P = 0.01) and latency (R = 0.67; P = 0.01), and increased with Hoehn & Yahr stage in the ‘off’ state (P = 0.02) from 5.7 (SD 3.5) (H&Y III) to 11.9 (SD 4.7) (H&Y IV). Walking speed correlated with changes in mean stride length, whereas cadence and gait variability did not. UPDRS gait score also reflected improving gait in the majority of subjects (8), providing clinical confirmation of the objective measures of the locomotor response to levodopa. Increasing abruptness (H) of the ‘off–on’ transition with disease duration is consistent with results from finger-tapping studies, and may reflect reduced buffering capacity of pre-synaptic nigrostriatal dopaminergic neurons. Ambulatory monitoring of gait objectively measures the dynamic locomotor response to levodopa, and this information could be used to improve daily management of motor fluctuations.

[1]  W. Ondo Investigational Pharmacological Treatments for Parkinson's Disease , 2003 .

[2]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[3]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[4]  J. Collins,et al.  Biomechanical gait alterations independent of speed in the healthy elderly: evidence for specific limiting impairments. , 1998, Archives of physical medicine and rehabilitation.

[5]  N. Quinn,et al.  Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality , 1998, Movement disorders : official journal of the Movement Disorder Society.

[6]  Jeffrey M. Hausdorff,et al.  Effects of Cognitive Challenge on Gait Variability in Patients with Parkinson’s Disease , 2003, Journal of geriatric psychiatry and neurology.

[7]  J. Gracies,et al.  Long-term monitoring of gait in Parkinson's disease. , 2007, Gait & posture.

[8]  V. Sossi,et al.  Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.

[9]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[10]  M. Contin,et al.  Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic–Dynamic Approach , 2001, Therapeutic drug monitoring.

[11]  W. Dunn,et al.  The ecology of human performance: a framework for considering the effect of context. , 1994, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[12]  J. Nutt On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.

[13]  Rajesh Pahwa,et al.  Stroke , 1987, Neurology.

[14]  M. Yekutiel Patients' fall records as an aid in designing and assessing therapy in Parkinsonism. , 1993, Disability and rehabilitation.

[15]  D. Woitalla,et al.  Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients , 2006, Clinical neuropharmacology.

[16]  P. Kempster,et al.  Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. Reyes-Parada,et al.  Delayed early morning turn “ON” in response to a single dose of levodopa in advanced Parkinson’s disease: pharmacokinetics should be considered , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  Jeffrey M. Hausdorff,et al.  Gait variability and basal ganglia disorders: Stride‐to‐stride variations of gait cycle timing in parkinson's disease and Huntington's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[19]  A. J. Stoessl,et al.  Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.

[20]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[21]  K L Siegel,et al.  Effects of bilateral posteroventral pallidotomy on gait of subjects with Parkinson disease. , 2000, Archives of neurology.

[22]  M. Vokaer,et al.  Effects of levodopa on upper limb mobility and gait in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[23]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[24]  J. Pailhous,et al.  Dopa-sensitive and Dopa-resistant gait parameters in Parkinson's disease , 1991, Journal of the Neurological Sciences.

[25]  Susan L. Mitchell,et al.  Patterns of Outcome Measurement in Parkinson’s Disease Clinical Trials , 2000, Neuroepidemiology.

[26]  J. Summers,et al.  Temporal stability of gait in Parkinson's disease. , 1996, Physical therapy.

[27]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[28]  A. Hughes,et al.  Gait analysis in patients with Parkinson's disease and motor fluctuations: Influence of levodopa and comparison with other measures of motor function , 1998, Movement disorders : official journal of the Movement Disorder Society.

[29]  B. Cohen,et al.  Effects of walking velocity on vertical head and body movements during locomotion , 1999, Experimental Brain Research.

[30]  Jeffrey M. Hausdorff,et al.  Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa , 2003, Journal of the Neurological Sciences.

[31]  M. Morris,et al.  The biomechanics and motor control of gait in Parkinson disease. , 2001, Clinical biomechanics.

[32]  M. Contin,et al.  Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease , 1996, Neurology.

[33]  S. Czaja,et al.  Practically relevant research: capturing real world tasks, environments, and outcomes. , 2003, The Gerontologist.

[34]  M. MacKay-Lyons Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease . , 1998, Physical therapy.

[35]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[36]  Nir Giladi,et al.  Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait , 2003, Experimental Brain Research.

[37]  R. Burdett,et al.  A comparison of gait characteristics in young and old subjects. , 1994, Physical therapy.

[38]  Jeffrey M. Hausdorff,et al.  Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena , 2004, Movement disorders : official journal of the Movement Disorder Society.

[39]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[40]  Hamish G MacDougall,et al.  Marching to the beat of the same drummer: the spontaneous tempo of human locomotion. , 2005, Journal of applied physiology.

[41]  G. Stelmach,et al.  Movement disorders: the importance of the movement context. , 1988, Journal of motor behavior.

[42]  Vesna Sossi,et al.  Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  M. Honda,et al.  Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease , 1999, Annals of neurology.